QIAGEN N.V. (QGEN) Stock Price, Forecast & Analysis

USA • New York Stock Exchange • NYSE:QGEN • NL0015002SN0

50.78 USD
-0.17 (-0.33%)
At close: Feb 9, 2026
50.78 USD
0 (0%)
After Hours: 2/9/2026, 8:26:39 PM

QGEN Key Statistics, Chart & Performance

Key Statistics
Market Cap11.01B
Revenue(TTM)N/A
Net Income(TTM)405.37M
Shares216.84M
Float215.76M
52 Week High57.82
52 Week Low39.61
Yearly DividendN/A
Dividend Yield0.52%
EPS(TTM)2.47
PE20.56
Fwd PE18.85
Earnings (Next)05-05
IPO1996-09-01
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
QGEN short term performance overview.The bars show the price performance of QGEN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5

QGEN long term performance overview.The bars show the price performance of QGEN in the last 1, 2 and 3 years. 1 year 2 years 3 years 5 10 15 20

The current stock price of QGEN is 50.78 USD. In the past month the price increased by 5.16%. In the past year, price increased by 21%.

QIAGEN N.V. / QGEN Daily stock chart

QGEN Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to QGEN. When comparing the yearly performance of all stocks, QGEN is one of the better performing stocks in the market, outperforming 73.36% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

QGEN Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to QGEN. While QGEN has a great profitability rating, there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

QGEN Financial Highlights

Over the last trailing twelve months QGEN reported a non-GAAP Earnings per Share(EPS) of 2.47. The EPS increased by 10.63% compared to the year before.


Industry RankSector Rank
PM (TTM) 19.58%
ROA 6.19%
ROE 11.11%
Debt/Equity 0.45
Chartmill High Growth Momentum
EPS Q2Q%1.64%
Sales Q2Q%3.69%
EPS 1Y (TTM)10.63%
Revenue 1Y (TTM)N/A

QGEN Forecast & Estimates

24 analysts have analysed QGEN and the average price target is 54.71 USD. This implies a price increase of 7.74% is expected in the next year compared to the current price of 50.78.

For the next year, analysts expect an EPS growth of 8.94% and a revenue growth 6.28% for QGEN


Analysts
Analysts72.5
Price Target54.71 (7.74%)
EPS Next Y8.94%
Revenue Next Year6.28%

QGEN Ownership

Ownership
Inst Owners85.46%
Ins Owners0.44%
Short Float %N/A
Short Ratio2.84

QGEN Competitors/Peers

The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
TMO THERMO FISHER SCIENTIFIC INC22.03205.423B
DHR DANAHER CORP25.51153.038B
BRKRP BRUKER CORP - BRKR 6 3/8 09/01/28150.0949.868B
A AGILENT TECHNOLOGIES INC21.0636.146B
IQV IQVIA HOLDINGS INC14.7332.812B
MTD METTLER-TOLEDO INTERNATIONAL29.8728.211B
WAT WATERS CORP22.6819.534B
ILMN ILLUMINA INC22.6517.916B
WST WEST PHARMACEUTICAL SERVICES31.7117.908B
MEDP MEDPACE HOLDINGS INC31.5514.94B

About QGEN

Company Profile

QGEN logo image QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,700 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Company Info

QIAGEN N.V.

Hulsterweg 82

Venlo LIMBURG 5912 NL

CEO: Thierry Bernard

Employees: 5700

QGEN Company Website

QGEN Investor Relations

Phone: 31773556600

QIAGEN N.V. / QGEN FAQ

Can you describe the business of QIAGEN N.V.?

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,700 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.


Can you provide the latest stock price for QIAGEN N.V.?

The current stock price of QGEN is 50.78 USD. The price decreased by -0.33% in the last trading session.


Does QGEN stock pay dividends?

QIAGEN N.V. (QGEN) has a dividend yield of 0.52%. The yearly dividend amount is currently 0.


What is the ChartMill technical and fundamental rating of QGEN stock?

QGEN has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Should I buy QGEN stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on QGEN.


Can you provide the number of employees for QIAGEN N.V.?

QIAGEN N.V. (QGEN) currently has 5700 employees.


Can you provide the upcoming earnings date for QIAGEN N.V.?

QIAGEN N.V. (QGEN) will report earnings on 2026-05-05, after the market close.